Table 1.

Characteristics of patients and clinical outcome.

			Compliance	Monthly migraine attack frequency
Patients	Sex	Age	Number of sessions	Before treatment	After treatment
1	M	36	U	6	2
2	F	45	>90	3	2
3	M	32	>90	4	2
4	M	69	>90	4	3
5	F	45	31	4	2
6	F	46	MV	MV	MV
7	F	49	>90	2	2
8	F	59	Drop out	–	–
9	F	37	71	4	4
10	F	26	20	MV	MV
11	F	22	46	5	2
12	F	18	5	1	0
13	F	40	35	5	5
14	F	26	87	3	2
> 30% of compliance (n = 10)
			Number of attacks/ month	MD	SA
		Before treatment	4.2 ± 1.1	7.3 ± 3.7	3 ± 2
		First month of treatment	2.6 ± 1.3	4.8 ± 2.7	1.4 ± 1.6
		Second month of treatment	2.8 ± 1.3	4.7 ± 2.3	1 ± 0.9
		Third month of treatment	2.6 ± 1.2	5.4 ± 4.4	2 ± 1.8

MV: missing value; M: male; F: female; U: unknown; eTNS: external trigeminal nerve stimulation; PET: positron emission tomography; MD: Migraine Days; SA: Severe Attacks.

Patient 1 used the device more than 30% of the time but sent the device back long after the end of the trial. Thus, her compliance during the three months could not be assessed as she continued to use eTNS daily and the number of recorded sessions was >150.

Patients in grey had a migraine attack during PET1. Patient 14 had an attack during PET2 only, and all patients were pain free during PET3.